指南与共识产科母胎医学

妊娠期肝内胆汁淤积症:母胎医学会与皇家妇产科医师学院指南的比较

Intrahepatic cholestasis of pregnancy: a comparison of Society for Maternal-Fetal Medicine and the Royal College of Obstetricians and Gynaecologists' guidelines.
指南 / 共识 · Am J Obstet Gynecol MFM · 2022-12-09

本文比较了母胎医学会2021年2月与皇家妇产科医师学院2022年6月发布的妊娠期肝内胆汁淤积症指南,涉及诊断、产前监测和分娩时机。两指南在胆汁酸诊断阈值、熊去氧胆酸使用、胎儿监测及分娩孕周分层上存在关键差异。

要点

  • 母胎医学会以瘙痒伴胆汁酸高于正常上限即诊断,皇家学院要求妊娠特异性胆汁酸≥19 mmol/L。
  • 母胎医学会推荐熊去氧胆酸为一线治疗,皇家学院因缺乏母胎获益证据建议不常规使用。
  • 母胎医学会推荐在异常胎儿检测可导致分娩的孕周行胎儿监测,皇家学院不推荐除胎动计数外的胎儿检测。

核心结论

  • 两学会妊娠期肝内胆汁淤积症指南在诊断、治疗、胎儿监测和分娩时机上存在多项关键差异。

研究设计与样本

  • 本文为文献综述,比较母胎医学会2021年2月与皇家妇产科医师学院2022年6月发布的妊娠期肝内胆汁淤积症指南。

主要发现

  • 诊断方面,母胎医学会认为瘙痒伴胆汁酸高于正常上限即可诊断,皇家学院要求胆汁酸≥19 mmol/L。
  • 治疗方面,母胎医学会推荐熊去氧胆酸为一线治疗,皇家学院建议不常规使用熊去氧胆酸。
  • 胎儿监测方面,母胎医学会推荐在异常胎儿检测可导致分娩的孕周进行监测,皇家学院不推荐除胎动计数外的胎儿检测。
  • 分娩时机方面,母胎医学会推荐胆汁酸<100 mmol/L于36-39周分娩,>100 mmol/L于36周分娩;皇家学院推荐系列胆汁酸评估并在35-40周间分层。

关键数值与推荐

  • 母胎医学会:瘙痒伴胆汁酸高于正常上限即诊断妊娠期肝内胆汁淤积症。
  • 皇家学院:妊娠特异性胆汁酸≥19 mmol/L诊断妊娠期肝内胆汁淤积症。
  • 母胎医学会:推荐熊去氧胆酸作为母体症状一线治疗。
  • 皇家学院:建议不常规使用熊去氧胆酸(因缺乏母胎获益证据)。
  • 母胎医学会:胆汁酸<100 mmol/L于36-39周分娩,>100 mmol/L于36周分娩。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study reviewed the literature regarding the diagnosis, antepartum surveillance, and timing of delivery of pregnancies complicated by intrahepatic cholestasis of pregnancy, comparing the guidelines published by the Society for Maternal-Fetal Medicine in February 2021 and those published by the Royal College of Obstetricians and Gynaecologists in the United Kingdom in June 2022. Several key differences exist in the clinical guidelines between the 2 organizations. With regard to the diagnosis of intrahepatic cholestasis of pregnancy, the Society for Maternal-Fetal Medicine considers any elevation in bile acids above the upper limit of normal in the setting of maternal pruritus diagnostic of intrahepatic cholestasis of pregnancy, whereas the Royal College of Obstetricians and Gynaecologists requires a pregnancy-specific elevated bile acid level of ≥19 mmol/L for diagnosis. Regarding the treatment of intrahepatic cholestasis of pregnancy, the Society for Maternal-Fetal Medicine recommends ursodeoxycholic acid as the first-line treatment of maternal symptoms. In contrast, the Royal College of Obstetricians and Gynaecologists specifically recommends against the routine use of ursodeoxycholic acid for intrahepatic cholestasis of pregnancy because of a lack of evidence regarding both maternal and fetal benefit. The Society for Maternal-Fetal Medicine recommends fetal surveillance at a gestational age when abnormal fetal testing would result in delivery being performed, whereas the Royal College of Obstetricians and Gynaecologists does not recommend any fetal testing beyond fetal kick count assessment. The Society for Maternal-Fetal Medicine recommends delivery at 36 to 39 weeks' gestation for intrahepatic cholestasis of pregnancy with bile acids <100 mmol/L and delivery at 36 weeks for bile acid levels >100 mmol/L. The Royal College of Obstetricians and Gynaecologists recommends serial assessment of bile acids with delivery timing stratified between 35- and 40-weeks' gestation according to bile acid levels.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Horgan R, Bitas C, Abuhamad A, et al. Intrahepatic cholestasis of pregnancy: a comparison of Society for Maternal-Fetal Medicine and the Royal College of Obstetricians and Gynaecologists' guidelines. Am J Obstet Gynecol MFM. 2022. PMID: 36503152. doi:10.1016/j.ajogmf.2022.100838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。